Nkarta (NKTX) EBT Margin (2019)

Nkarta's (NKTX) quarterly EBT Margin came in at 1638637.4% in Q3 2019, up 879.95% quarter-over-quarter from 210093.89% in Q2 2019.

Nkarta (NKTX) EBT Margin (2019) Analysis & Trends

Nkarta's EBT Margin history runs 1 years deep, the most recent figure standing at 1638637.4% for Q3 2019.

On a quarterly basis, EBT Margin changed N/A year-over-year to 1638637.4% in Q3 2019; TTM through Dec 2020 was 13714285.71%, a N/A change from a year earlier, with the FY2019 full-year figure at 20461.74%, changed N/A from the prior year.
EBT Margin rose to 1638637.4% in Q3 2019 per NKTX's latest filing, from 210093.89% in the prior quarter.
Across five years, EBT Margin topped out at 1638637.4% in Q3 2019 and bottomed at 210093.89% in Q2 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Nkarta	170.79 Mn	170.79 Mn	-	-

Historic Data

Download Data

Date	Value
Sep 30, 2019	1,638,637.40%
Jun 30, 2019	-210,093.89%